celecoxib has been researched along with Adverse Drug Event in 25 studies
| Excerpt | Relevance | Reference |
|---|---|---|
| "This study aimed to assess the relative efficacy and tolerability of etoricoxib, celecoxib, and naproxen at recommended dosages in patients with osteoarthritis (OA)." | 8.93 | Relative efficacy and tolerability of etoricoxib, celecoxib, and naproxen in the treatment of osteoarthritis : A Bayesian network meta-analysis of randomized controlled trials based on patient withdrawal. ( Choi, SJ; Ji, JD; Kim, JH; Lee, YH; Seo, YH; Song, GG, 2016) |
| " In this survey, the prescribed dosage was reduced or discontinued in 150 and 56 patients, respectively, receiving celecoxib and diclofenac prescribed alone, as recorded in a Japanese database of adverse drug events." | 8.31 | Plasma and Hepatic Exposures of Celecoxib and Diclofenac Prescribed Alone in Patients with Cytochrome P450 2C9*3 Modeled after Virtual Oral Administrations and Likely Associated with Adverse Drug Events Reported in a Japanese Database. ( Adachi, K; Murayama, N; Nakano, H; Ohyama, K; Saito, Y; Sato, T; Shimizu, M; Tanaka, Y; Yamazaki, H, 2023) |
| "To evaluate the efficacy and safety of naproxen and celecoxib for the primary prevention of Alzheimer disease (AD)." | 5.12 | Naproxen and celecoxib do not prevent AD in early results from a randomized controlled trial. ( Breitner, JC; Green, RC; Lyketsos, CG; Martin, BK; Meinert, C; Piantadosi, S; Sabbagh, M, 2007) |
| "This study aimed to assess the relative efficacy and tolerability of etoricoxib, celecoxib, and naproxen at recommended dosages in patients with osteoarthritis (OA)." | 4.93 | Relative efficacy and tolerability of etoricoxib, celecoxib, and naproxen in the treatment of osteoarthritis : A Bayesian network meta-analysis of randomized controlled trials based on patient withdrawal. ( Choi, SJ; Ji, JD; Kim, JH; Lee, YH; Seo, YH; Song, GG, 2016) |
| " In this survey, the prescribed dosage was reduced or discontinued in 150 and 56 patients, respectively, receiving celecoxib and diclofenac prescribed alone, as recorded in a Japanese database of adverse drug events." | 4.31 | Plasma and Hepatic Exposures of Celecoxib and Diclofenac Prescribed Alone in Patients with Cytochrome P450 2C9*3 Modeled after Virtual Oral Administrations and Likely Associated with Adverse Drug Events Reported in a Japanese Database. ( Adachi, K; Murayama, N; Nakano, H; Ohyama, K; Saito, Y; Sato, T; Shimizu, M; Tanaka, Y; Yamazaki, H, 2023) |
| "In this analysis of the Italian spontaneous reporting system database, we found new urinary retention signals, requiring further evaluation, for dapagliflozin, gabapentin, lithium, celecoxib, and piroxicam." | 4.12 | Drug-induced Urinary Retention: An Analysis of a National Spontaneous Adverse Drug Reaction Reporting Database. ( Crisafulli, S; Cutroneo, PM; Di Giovanni, V; Ferrajolo, C; Ficarra, V; Sottosanti, L; Spina, E; Trifirò, G; Verhamme, K, 2022) |
| "Celecoxib is a non-steroidal anti-inflammatory drug (NSAID) and a representative selective cyclooxygenase (COX)-2 inhibitor, which is commonly prescribed for osteoarthritis, rheumatoid arthritis, ankylosing spondylitis, acute pain, and primary dysmenorrhea." | 3.01 | Physiologically based pharmacokinetic (PBPK) modeling for prediction of celecoxib pharmacokinetics according to CYP2C9 genetic polymorphism. ( Bae, JW; Cho, CK; Jang, CG; Jung, EH; Kang, P; Kim, YH; Lee, SY; Lee, YJ; Park, HJ, 2021) |
| " The risk score was designed to predict the 1-year occurrence of major toxicity among NSAID users, including major adverse cardiovascular events, acute kidney injury, significant gastrointestinal events, and mortality." | 2.90 | Derivation and Validation of a Major Toxicity Risk Score Among Nonsteroidal Antiinflammatory Drug Users Based on Data From a Randomized Controlled Trial. ( Husni, ME; Nissen, S; Paynter, N; Shao, M; Solomon, DH; Wolski, K, 2019) |
| "The multiple drug interactions in which CAIs are involved should be carefully considered when such drugs are used in combination with the drug classes mentioned above, as the risks of developing toxicity and serious side effects if the dosages are not adjusted are high." | 2.53 | Drug interaction considerations in the therapeutic use of carbonic anhydrase inhibitors. ( Supuran, CT, 2016) |
| "Juvenile toxicology studies in animals provide useful information to guide monitoring of potential adverse effects in children especially on growth and development." | 2.45 | Essentials for starting a pediatric clinical study (4): Clinical pediatric safety planning based on preclinical toxicity studies and pediatric pharmacovigilance guidance. ( Sheth, N, 2009) |
| "Nonsteroidal anti-inflammatory drugs (NSAIDs), which are globally prescribed, exhibit mainly anti-inflammatory and analgesic effects but also can cause adverse effects including gastrointestinal erosions, ulceration, bleeding, and perforation." | 1.43 | (1)H-Nuclear magnetic resonance-based metabolic profiling of nonsteroidal anti-inflammatory drug-induced adverse effects in rats. ( Choi, KH; Chung, MW; Lee, HJ; Park, JH; Um, SY, 2016) |
| " All adverse events (AEs) regardless of severity were captured in the database." | 1.40 | Safety of celecoxib and nonselective nonsteroidal anti-inflammatory drugs in juvenile idiopathic arthritis: results of the Phase 4 registry. ( Abramsky, S; Brunner, HI; Chalom, EC; Giannini, EH; Goldsmith, DP; Gottlieb, BS; Jung, LK; Lovell, DJ; Morris, PW; Nanda, K; Onel, KB; Petiniot, L; Shishov, M; Sobel, RE; Weiss, JE; Young, JP, 2014) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 10 (40.00) | 29.6817 |
| 2010's | 11 (44.00) | 24.3611 |
| 2020's | 4 (16.00) | 2.80 |
| Authors | Studies |
|---|---|
| Pedersen, JM | 1 |
| Matsson, P | 1 |
| Bergström, CA | 1 |
| Norinder, U | 1 |
| Hoogstraate, J | 1 |
| Artursson, P | 1 |
| Liu, Z | 1 |
| Shi, Q | 1 |
| Ding, D | 1 |
| Kelly, R | 1 |
| Fang, H | 1 |
| Tong, W | 1 |
| Morgan, RE | 1 |
| van Staden, CJ | 1 |
| Chen, Y | 1 |
| Kalyanaraman, N | 1 |
| Kalanzi, J | 1 |
| Dunn, RT | 1 |
| Afshari, CA | 1 |
| Hamadeh, HK | 1 |
| Adachi, K | 1 |
| Ohyama, K | 1 |
| Tanaka, Y | 1 |
| Nakano, H | 1 |
| Sato, T | 1 |
| Murayama, N | 1 |
| Shimizu, M | 1 |
| Saito, Y | 1 |
| Yamazaki, H | 1 |
| Okamura, T | 1 |
| Isogai, S | 1 |
| Yamamoto, N | 1 |
| Niwa, Y | 1 |
| Inoue, T | 2 |
| Shingo, M | 1 |
| Ina, T | 1 |
| Yuri, M | 1 |
| Goto, Y | 1 |
| Kondo, M | 1 |
| Imaizumi, K | 1 |
| Crisafulli, S | 1 |
| Cutroneo, PM | 1 |
| Verhamme, K | 1 |
| Ferrajolo, C | 1 |
| Ficarra, V | 1 |
| Sottosanti, L | 1 |
| Di Giovanni, V | 1 |
| Spina, E | 1 |
| Trifirò, G | 1 |
| Kim, YH | 1 |
| Kang, P | 1 |
| Cho, CK | 1 |
| Jung, EH | 1 |
| Park, HJ | 1 |
| Lee, YJ | 1 |
| Bae, JW | 1 |
| Jang, CG | 1 |
| Lee, SY | 1 |
| Solomon, DH | 1 |
| Shao, M | 1 |
| Wolski, K | 1 |
| Nissen, S | 1 |
| Husni, ME | 1 |
| Paynter, N | 1 |
| Iijima, H | 1 |
| Arimitsu, J | 1 |
| Hagihara, K | 1 |
| Kawai, S | 1 |
| Shiraishi, E | 1 |
| Hiyama, S | 1 |
| Mukai, A | 1 |
| Shinzaki, S | 1 |
| Nishida, T | 1 |
| Ogata, A | 1 |
| Tsujii, M | 1 |
| Takehara, T | 1 |
| Sobel, RE | 1 |
| Lovell, DJ | 1 |
| Brunner, HI | 1 |
| Weiss, JE | 1 |
| Morris, PW | 1 |
| Gottlieb, BS | 1 |
| Chalom, EC | 1 |
| Jung, LK | 1 |
| Onel, KB | 1 |
| Petiniot, L | 1 |
| Goldsmith, DP | 1 |
| Nanda, K | 1 |
| Shishov, M | 1 |
| Abramsky, S | 1 |
| Young, JP | 1 |
| Giannini, EH | 1 |
| Barozzi, N | 1 |
| Peeters, GM | 1 |
| Tett, SE | 1 |
| Song, GG | 1 |
| Seo, YH | 1 |
| Kim, JH | 1 |
| Choi, SJ | 1 |
| Ji, JD | 1 |
| Lee, YH | 1 |
| Supuran, CT | 1 |
| Um, SY | 1 |
| Park, JH | 1 |
| Chung, MW | 1 |
| Choi, KH | 1 |
| Lee, HJ | 1 |
| Dubois, RN | 1 |
| Sheth, N | 1 |
| Jansen, JP | 1 |
| Gaugris, S | 1 |
| Choy, EH | 1 |
| Ostor, A | 1 |
| Nash, JT | 1 |
| Stam, W | 1 |
| Cassels, A | 1 |
| Hughes, MA | 1 |
| Cole, C | 1 |
| Mintzes, B | 1 |
| Lexchin, J | 1 |
| McCormack, JP | 1 |
| Buckstein, R | 1 |
| Kerbel, RS | 1 |
| Shaked, Y | 1 |
| Nayar, R | 1 |
| Foden, C | 1 |
| Turner, R | 1 |
| Lee, CR | 1 |
| Taylor, D | 1 |
| Zhang, L | 1 |
| Man, S | 1 |
| Baruchel, S | 1 |
| Stempak, D | 1 |
| Bertolini, F | 1 |
| Crump, M | 1 |
| Young, D | 1 |
| Lyketsos, CG | 1 |
| Breitner, JC | 1 |
| Green, RC | 1 |
| Martin, BK | 1 |
| Meinert, C | 1 |
| Piantadosi, S | 1 |
| Sabbagh, M | 1 |
| Audia, P | 1 |
| Feinfeld, DA | 1 |
| Dubrow, A | 1 |
| Winchester, JF | 1 |
| Dragovich, T | 1 |
| Burris, H | 1 |
| Loehrer, P | 1 |
| Von Hoff, DD | 1 |
| Chow, S | 1 |
| Stratton, S | 1 |
| Green, S | 1 |
| Obregon, Y | 1 |
| Alvarez, I | 1 |
| Gordon, M | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| A Randomized, Double Blind, Parallel-group Study Of Cardiovascular Safety In Osteoarthritis Or Rheumatoid Arthritis Patients With Or At High Risk For Cardiovascular Disease Comparing Celecoxib With Naproxen And Ibuprofen[NCT00346216] | Phase 4 | 24,081 participants (Actual) | Interventional | 2006-10-04 | Completed | ||
| SINCERE™: Safety in Idiopathic Arthritis: NSAIDs and Celebrex Evaluation Registry A Prospective Observational Registry Of Patients With Juvenile Idiopathic Arthritis (JIA) Treated With NSAIDs[NCT00688545] | 275 participants (Actual) | Observational | 2009-04-30 | Terminated (stopped due to See termination reason in detailed description.) | |||
| An Open-label, Multi-center, Phase 1b Study to Investigate the Safety and Tolerability of SLC-0111 (WBI-5111) in Combination With Gemcitabine in Metastatic Pancreatic Ductal Adenocarcinoma Subjects Positive for Carbonic Anhydrase IX[NCT03450018] | Phase 1/Phase 2 | 30 participants (Anticipated) | Interventional | 2019-01-10 | Recruiting | ||
| A Single Center, Randomized, Double-blind, Placebo-controlled 2-way Crossover Study to Investigate the Mechanism of Action of Etoricoxib in Subjects With Osteoarthritis Knee Pain.[NCT01619150] | Phase 2 | 39 participants (Actual) | Interventional | 2012-07-31 | Completed | ||
| Alzheimer's Disease Anti-Inflammatory Prevention Trial (ADAPT)[NCT00007189] | Phase 3 | 2,625 participants | Interventional | 2001-01-31 | Completed | ||
| Alzheimer's Disease Anti-Inflammatory Prevention Trial Follow-Up Study[NCT01417130] | 1,650 participants (Anticipated) | Observational | 2009-08-31 | Active, not recruiting | |||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
"VAS question How much pain do you have was graded on a scale from 0 to 100 with 0 indicating No pain and 100 indicating Worst possible pain." (NCT00346216)
Timeframe: ITT and MITT Population - Baseline to 42 months
| Intervention | Number of participants (Mean) | |||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Baseline (ITT) N= 8014, 8001, 7928 | Change-Baseline to Mon1 (ITT) N=7382, 7379, 7325 | Change-Baseline to Mon2 (ITT) N=7180, 7090, 7149 | Change-Baseline to Mon4 (ITT) N=6777, 6696, 6740 | Change-Baseline to Mon8 (ITT) N=6230, 6137, 6159 | Change-Baseline to Mon12 (ITT) N=5792, 5696, 5846 | Change-Baseline to Mon18 (ITT) N=5310, 5181. 5246 | Change-Baseline to Mon24 (ITT) N=4818, 4776, 4785 | Change-Baseline to Mon30 (ITT) N=4140, 4069, 4086 | Change-Baseline to Mon36 (ITT) N=3692, 3627, 3635 | Change-Baseline to Mon42 (ITT) N=3469, 3406, 3439 | Baseline (MITT) N=7974, 7954, 7894 | Change-Baseline to Mon1 MITT N=7372, 7367, 7321 | Change-Baseline to Mon2 MITT N=7170, 7078, 7142 | Change-Baseline to Mon4 MITT N=6772, 6686, 6732 | Change-Baseline to Mon8 MITT N=6224, 6128, 6155 | Change-Baseline to Mon12 MITT N=5787, 5689, 5844 | Change-Baseline to Mon18 MITT N=5305, 5175, 5242 | Change-Baseline to Mon24 MITT N=4815, 4769, 4782 | Change-Baseline to Mon30 MITT N=4139, 4067, 4085 | Change-Baseline to Mon36 MITT N=3691, 3623, 3635 | Change-Baseline to Mon42 MITT N=3468, 3404, 3438 | |
| Celecoxib | 54.0 | -8.2 | -10.5 | -11.4 | -11.7 | -11.0 | -11.3 | -11.3 | -10.5 | -10.1 | -11.4 | 54.0 | -8.2 | -10.5 | -11.4 | -11.7 | -11.0 | -11.3 | -11.4 | -10.5 | -10.2 | -11.4 |
| Ibuprofen | 54.1 | -9.0 | -10.6 | -11.7 | -12.1 | -11.6 | -11.3 | -11.5 | -11.2 | -10.7 | -11.1 | 54.1 | -9.0 | -10.6 | -11.7 | -12.1 | -11.6 | -11.3 | -11.5 | -11.2 | -10.7 | -11.1 |
| Naproxen | 54.1 | -9.9 | -11.1 | -12.3 | -12.1 | -11.9 | -11.7 | -11.4 | -11.3 | -11.6 | -12.1 | 54.1 | -9.9 | -11.1 | -12.3 | -12.1 | -11.9 | -11.7 | -11.3 | -11.3 | -11.6 | -12.1 |
MACE defined as the composite of CV death (including hemorrhagic death), non-fatal MI, non-fatal stroke, hospitalization for UA, revascularization or hospitalization for TIA (NCT00346216)
Timeframe: ITT Population - 30 months; MITT Population - 42 months
| Intervention | Percentage of Participants (Number) | |
|---|---|---|
| ITT (N = 8072, 8040, 7969) | MITT (N = 8030, 7990, 7933) | |
| Celecoxib | 4.2 | 3.1 |
| Ibuprofen | 4.8 | 3.6 |
| Naproxen | 4.3 | 3.2 |
APTC events are defined as a composite of any of the following events: Death due to CV causes (including cardiac, cerebrovascular, venous thromboembolic, haemorrhagic, other vascular, or unknown cause); Non-fatal MI; Non-fatal stroke (including intracranial hemorrhages, stroke of ischemic or unknown etiology). (NCT00346216)
Timeframe: Intent to Treat (ITT) Population - 30 months; Modified ITT (MITT) Population - 42 months
| Intervention | Percentage of Partcipants (Number) | |
|---|---|---|
| ITT (N = 8072, 8040, 7969) | MITT (N = 8030, 7990, 7933) | |
| Celecoxib | 2.3 | 1.7 |
| Ibuprofen | 2.7 | 1.9 |
| Naproxen | 2.5 | 1.8 |
CSGIE include: Gastroduodenal (GD) hemorrhage, Gastric outlet obstruction, Gastroduodenal, small bowel or large bowel perforation, Large bowel hemorrhage, Small bowel hemorrhage, Acute GI hemorrhage of unknown origin, including presumed small bowel hemorrhage, Symptomatic gastric or duodenal ulcer (NCT00346216)
Timeframe: ITT Population - 30 months; MITT Population - 42 months
| Intervention | Percentage of Participants (Number) | |
|---|---|---|
| ITT (N = 8072, 8040, 7969) | MITT (N = 8030, 7990, 7933) | |
| Celecoxib | 0.7 | 0.3 |
| Ibuprofen | 0.9 | 0.7 |
| Naproxen | 0.7 | 0.7 |
JIA medications by class: GI protective agents (eg, proton-pump inhibitors, antacids, surcalfate), other GI, DMARDs, biologics, antihypertensives, NSAIDs (Celecoxib, Diclofenac, Ibuprofen, Meloxicam, Naproxen, other NSAIDs), corticosteroids (oral, IV, intra-articular, other forms), analgesics Acetaminophen, Opioids, other). Participants could receive more than 1 medication. (NCT00688545)
Timeframe: Year 2 or early termination
| Intervention | Participants (Number) | |||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| GI protective agents | Other GI | DMARDs | Biologics | Antihypertensives | NSAIDs (Celecoxib) | NSAIDs (Diclofenac) | NSAIDs (Ibuprofen) | NSAIDs (Meloxicam) | NSAIDs (Naproxen) | NSAIDs (Other) | Corticosteroids (oral, IV, intra-articular) | Corticosteroids (Other) | Analgesics (Acetaminophen, Opioids, Other) | |
| Celecoxib | 20 | 5 | 24 | 13 | 1 | 7 | 0 | 1 | 1 | 0 | 0 | 4 | 2 | 11 |
| nsNSAIDs | 54 | 8 | 102 | 60 | 4 | 2 | 0 | 9 | 8 | 7 | 3 | 15 | 6 | 19 |
Counts of participants who had treatment-emergent adverse events (TEAEs), defined as newly occurring or worsening after first dose. Participants with multiple occurrences of an AE within a category were counted once within the category. AEs attributed to the NSAID (celecoxib or nsNSAID) utilized at time of event, regardless of the initial NSAID treatment at Registry entry. (NCT00688545)
Timeframe: Baseline up to 2 years
| Intervention | Participants (Number) | |
|---|---|---|
| AEs | SAEs | |
| Celecoxib | 36 | 2 |
| nsNSAIDs | 117 | 9 |
4 reviews available for celecoxib and Adverse Drug Event
| Article | Year |
|---|---|
Relative efficacy and tolerability of etoricoxib, celecoxib, and naproxen in the treatment of osteoarthritis : A Bayesian network meta-analysis of randomized controlled trials based on patient withdrawal.
Topics: Aged; Aged, 80 and over; Anti-Inflammatory Agents; Bayes Theorem; Celecoxib; Dose-Response Relations | 2016 |
Drug interaction considerations in the therapeutic use of carbonic anhydrase inhibitors.
Topics: Acetazolamide; Anti-Inflammatory Agents, Non-Steroidal; Anti-Obesity Agents; Antibodies, Monoclonal; | 2016 |
New, long-term insights from the Adenoma Prevention with Celecoxib Trial on a promising but troubled class of drugs.
Topics: Adenoma; Anti-Inflammatory Agents, Non-Steroidal; Cardiovascular Diseases; Cardiovascular System; Ce | 2009 |
Essentials for starting a pediatric clinical study (4): Clinical pediatric safety planning based on preclinical toxicity studies and pediatric pharmacovigilance guidance.
Topics: Adverse Drug Reaction Reporting Systems; Animals; Anti-Inflammatory Agents, Non-Steroidal; Arthritis | 2009 |
6 trials available for celecoxib and Adverse Drug Event
| Article | Year |
|---|---|
Physiologically based pharmacokinetic (PBPK) modeling for prediction of celecoxib pharmacokinetics according to CYP2C9 genetic polymorphism.
Topics: Administration, Oral; Celecoxib; Cyclooxygenase 2 Inhibitors; Cytochrome P-450 CYP2C9; Drug-Related | 2021 |
Derivation and Validation of a Major Toxicity Risk Score Among Nonsteroidal Antiinflammatory Drug Users Based on Data From a Randomized Controlled Trial.
Topics: Aged; Anti-Inflammatory Agents, Non-Steroidal; Arthritis, Rheumatoid; Cardiovascular Diseases; Celec | 2019 |
Amelioration of small bowel injury by switching from nonselective nonsteroidal anti-inflammatory drugs to celecoxib in rheumatoid arthritis patients: a pilot study.
Topics: Aged; Anti-Inflammatory Agents, Non-Steroidal; Arthritis, Rheumatoid; Capsule Endoscopy; Celecoxib; | 2014 |
High-Dose celecoxib and metronomic "low-dose" cyclophosphamide is an effective and safe therapy in patients with relapsed and refractory aggressive histology non-Hodgkin's lymphoma.
Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Celecoxib; Cyclophosphamide; Disease Progressi | 2006 |
Naproxen and celecoxib do not prevent AD in early results from a randomized controlled trial.
Topics: Adult; Aged; Alzheimer Disease; Anti-Inflammatory Agents, Non-Steroidal; Brain; Celecoxib; Cyclooxyg | 2007 |
Naproxen and celecoxib do not prevent AD in early results from a randomized controlled trial.
Topics: Adult; Aged; Alzheimer Disease; Anti-Inflammatory Agents, Non-Steroidal; Brain; Celecoxib; Cyclooxyg | 2007 |
Naproxen and celecoxib do not prevent AD in early results from a randomized controlled trial.
Topics: Adult; Aged; Alzheimer Disease; Anti-Inflammatory Agents, Non-Steroidal; Brain; Celecoxib; Cyclooxyg | 2007 |
Naproxen and celecoxib do not prevent AD in early results from a randomized controlled trial.
Topics: Adult; Aged; Alzheimer Disease; Anti-Inflammatory Agents, Non-Steroidal; Brain; Celecoxib; Cyclooxyg | 2007 |
Gemcitabine plus celecoxib in patients with advanced or metastatic pancreatic adenocarcinoma: results of a phase II trial.
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Celecoxib; Deoxycytidine; Drug-Relat | 2008 |
15 other studies available for celecoxib and Adverse Drug Event
| Article | Year |
|---|---|
Prediction and identification of drug interactions with the human ATP-binding cassette transporter multidrug-resistance associated protein 2 (MRP2; ABCC2).
Topics: Administration, Oral; Animals; Antineoplastic Agents; Antipsychotic Agents; Antiviral Agents; ATP Bi | 2008 |
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
Topics: Animals; Anti-Infective Agents; Anti-Inflammatory Agents; Chemical and Drug Induced Liver Injury; Da | 2011 |
A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.
Topics: Animals; ATP Binding Cassette Transporter, Subfamily B; ATP Binding Cassette Transporter, Subfamily | 2013 |
Plasma and Hepatic Exposures of Celecoxib and Diclofenac Prescribed Alone in Patients with Cytochrome P450 2C9*3 Modeled after Virtual Oral Administrations and Likely Associated with Adverse Drug Events Reported in a Japanese Database.
Topics: Administration, Oral; Celecoxib; Cytochrome P-450 CYP2C9; Cytochrome P-450 Enzyme System; Diclofenac | 2023 |
Celecoxib induced respiratory symptoms without urinary LTE 4 increase in a patient with AERD.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Asthma, Aspirin-Induced; Celecoxib; Drug-Related Side Effec | 2021 |
Drug-induced Urinary Retention: An Analysis of a National Spontaneous Adverse Drug Reaction Reporting Database.
Topics: Adverse Drug Reaction Reporting Systems; Celecoxib; Drug-Related Side Effects and Adverse Reactions; | 2022 |
Safety of celecoxib and nonselective nonsteroidal anti-inflammatory drugs in juvenile idiopathic arthritis: results of the Phase 4 registry.
Topics: Adolescent; Anti-Inflammatory Agents, Non-Steroidal; Arthritis, Juvenile; Celecoxib; Child; Child, P | 2014 |
Actions following adverse drug events - how do these influence uptake and utilisation of newer and/or similar medications?
Topics: Aged; Australia; Bone Density Conservation Agents; Celecoxib; Cyclooxygenase 2 Inhibitors; Diphospho | 2015 |
(1)H-Nuclear magnetic resonance-based metabolic profiling of nonsteroidal anti-inflammatory drug-induced adverse effects in rats.
Topics: Animals; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Celecoxib; Cyclooxygenase 2 Inhibitors; D | 2016 |
Cost effectiveness of etoricoxib versus celecoxib and non-selective NSAIDS in the treatment of ankylosing spondylitis.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Bayes Theorem; Celecoxib; Cost-Benefit Analysis; Cyclooxyge | 2010 |
[Inflammation-induced pain. How rheumatism patients profit from the proper NSAID choice].
Topics: Aged; Anti-Inflammatory Agents, Non-Steroidal; Arthritis, Rheumatoid; Celecoxib; Drug-Related Side E | 2012 |
Drugs in the news: an analysis of Canadian newspaper coverage of new prescription drugs.
Topics: Acetamides; Advertising; Anti-Inflammatory Agents, Non-Steroidal; Anticholesteremic Agents; Antivira | 2003 |
Lessons to learn from the COX-2 saga. Yes, FDA reforms are needed. And marketing distorts how medications are used. But one moral to the story is that all drugs have risks.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Cardiovascular Diseases; Celecoxib; Cyclooxygenase 2 Inhibi | 2005 |
FDA advisers endorse Celebrex for juvenile rheumatoid arthritis: lack of studies in children raises safety concerns.
Topics: Adolescent; Anti-Inflammatory Agents, Non-Steroidal; Arthritis, Juvenile; Biomedical Research; Celec | 2007 |
Metformin-induced lactic acidosis and acute pancreatitis precipitated by diuretic, celecoxib, and candesartan-associated acute kidney dysfunction.
Topics: Acidosis, Lactic; Acute Disease; Acute Kidney Injury; Angiotensin II Type 1 Receptor Blockers; Benzi | 2008 |